Economic burden of Respiratory Syncytial Virus Infection in Colombia in 2019: A Cost-of-Illness Study
Preprint
Abstract
Background: Respiratory Syncytial Virus (RSV) is one of the leading causes of acute respiratory infections and severe cases can lead to hospitalization or death. The epidemiology and health resource utilization of RSV infection in Colombia is not well understood. Given the recent availability of new RSV preventatives, this study estimated the economic burden of RSV in Colombia. Methods: This cost-of-illness study employed a retrospective cohort design and bottom-up costing approach to estimate direct healthcare costs associated with RSV-related acute respiratory infections (ARI) across pediatric and adult populations. Administrative data from sentinel surveillance centers belonging to the National Epidemiological Surveillance System of the Colombian National Institute of Health, the database for the study of the Capitation Payment Unit database, and the Integrated Social Protection Information System were utilized to estimate RSV incidence, mortality, and healthcare costs. Costs were expressed in U.S. dollars (USD). Results: A total of 264,744 RSV-related healthcare consultations were identified in 2019. The highest incidence was among infants under one year (61.8 per 1,000), while general mortality was highest in adults ≥75 years (46.6 per 100,000), followed by infants (42.4 per 100,000). Total direct healthcare costs were estimated at $682.87 million (95% CI: $281.39–$1,084.35 million), with the largest share, contributed by individuals aged ≥15 years. Among infants under one year, ICU patients had the highest average cost ($3,619), and hospitalization accounted for 49% of total spending, followed by ICU care (29%) and medications (8%). Conclusions: RSV poses a significant economic burden on Colombia’s healthcare system. These findings support the need for targeted prevention strategies and efficient resource allocation. Future research should incorporate indirect costs and long-term impacts. Highlights: The study provides the first national-level estimate of the economic burden of RSV in Colombia using comprehensive administrative data. The highest incidence and healthcare costs are observed in infants under one year and adults over 75, highlighting the need for targeted prevention strategies. The findings can inform health policy and resource allocation decisions in Colombia’s universal healthcare system.Keywords
This publication has 31 references indexed in Scilit:
- Respiratory syncytial virus-attributable hospitalizations among adults in high- and middle-income countries: application of the Global Burden of Disease frameworkeClinicalMedicine, 2025
- Respiratory Syncytial Virus Infection: An UpdateIndian Journal of Pediatrics, 2023
- Incidence of Respiratory Syncytial Virus Infection in Older Adults: Limitations of Current DataInfectious Diseases and Therapy, 2023
- Diagnosis of Respiratory Syncytial Virus in Adults Substantially Increases When Adding Sputum, Saliva, and Serology Testing to Nasopharyngeal Swab RT–PCRInfectious Diseases and Therapy, 2023
- Adjusting for Case Under-Ascertainment in Estimating RSV Hospitalisation Burden of Older Adults in High-Income Countries: a Systematic Review and Modelling StudyInfectious Diseases and Therapy, 2023
- Costs of Respiratory Syncytial Virus Hospitalizations in ColombiaPharmacoEconomics - Open, 2020
- Direct medical costs of RSV-related bronchiolitis hospitalizations in a middle-income tropical countryAllergologia et Immunopathologia, 2020
- Respiratory Syncytial Virus InfectionClinics in Chest Medicine, 2017
- Clinical and Epidemiologic Features of Respiratory Syncytial Virus2013
- Consequences of Immature and Senescent Immune Responses for Infection with Respiratory Syncytial Virus2013